PurposeTo assess the awareness of biosimilar intravitreal anti-VEGF agents among retina specialists practicing in the United States (US) and Europe.MethodsA 16-question online survey was created in English and distributed between Dec 01, 2021 and Jan 31, 2022. A total of 112 respondents (retinal physicians) from the US and Europe participated.ResultsThe majority of the physicians (56.3%) were familiar with anti-VEGF biosimilars. A significant number of physicians needed more information (18.75%) and real world data (25%) before switching to a biosimilar. About one half of the physicians were concerned about biosimilar safety (50%), efficacy (58.9 %), immunogenicity (50%), and their efficacy with extrapolated indications (67.8 %). Retinal physicians from the US were less inclined to shift from off-label bevacizumab to biosimilar ranibizumab or on-label bevacizumab (if approved) compared to physicians from Europe (p=0.0001). Furthermore, physicians from the US were more concerned about biosimilar safety (p=0.0371) and efficacy compared to Europe (p= 0.0078). ConclusionsThe Bio-USER survey revealed that while the majority of retinal physicians need additional information regarding the safety, efficacy and immunogenicity when making clinical decisions regarding their use. Retinal physicians from US are more comfortable in continuing to use off-label bevacizumab compared to physicians from Europe.

Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER - survey) / Sharma, Ashish; Holz, Frank G; Regillo, Carl D; Freund, K Bailey; Sarraf, David; Khanani, Arshad M; Baumal, Caroline; Holekamp, Nancy; Tadayoni, Ramin; Kumar, Nilesh; Parachuri, Nikulaa; Kuppermann, Baruch D; Bandello, Francesco; Querques, Giuseppe; Loewenstein, Anat; Özdek, Şengül; Rezai, Kourous; Laurent, Kodjikian; Bilgic, Alper; Lanzetta, Paolo; Zur, Dinah; Yannuzzi, Nicolas; Corradetti, Giulia; Kaiser, Peter; Hilely, Assaf; Boyer, David; Rachitskaya, Aleksandra; Chakravarthy, Usha; Wintergerst, Maximilian; Sarao, Valentina; Parolini, Barbara; Mruthyunjaya, Prithvi; Nguyen, Quan Dong; Do, Diana; Keane, Pearse A; Hassan, Tarek; Sridhar, Jayanth; Eichenbaum, David; Grewal, Dilraj; Splitzer, Martin. - In: EXPERT OPINION ON BIOLOGICAL THERAPY. - ISSN 1744-7682. - (2023), pp. 1-9. [10.1080/14712598.2023.2176218]

Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER - survey)

Bandello, Francesco;Querques, Giuseppe;
2023-01-01

Abstract

PurposeTo assess the awareness of biosimilar intravitreal anti-VEGF agents among retina specialists practicing in the United States (US) and Europe.MethodsA 16-question online survey was created in English and distributed between Dec 01, 2021 and Jan 31, 2022. A total of 112 respondents (retinal physicians) from the US and Europe participated.ResultsThe majority of the physicians (56.3%) were familiar with anti-VEGF biosimilars. A significant number of physicians needed more information (18.75%) and real world data (25%) before switching to a biosimilar. About one half of the physicians were concerned about biosimilar safety (50%), efficacy (58.9 %), immunogenicity (50%), and their efficacy with extrapolated indications (67.8 %). Retinal physicians from the US were less inclined to shift from off-label bevacizumab to biosimilar ranibizumab or on-label bevacizumab (if approved) compared to physicians from Europe (p=0.0001). Furthermore, physicians from the US were more concerned about biosimilar safety (p=0.0371) and efficacy compared to Europe (p= 0.0078). ConclusionsThe Bio-USER survey revealed that while the majority of retinal physicians need additional information regarding the safety, efficacy and immunogenicity when making clinical decisions regarding their use. Retinal physicians from US are more comfortable in continuing to use off-label bevacizumab compared to physicians from Europe.
2023
Anti-VEGF
Bio-USER
United States
awareness
biosimilar
europe
ophthalmology
retina
survey
File in questo prodotto:
File Dimensione Formato  
Biosimilars for retinal diseases United States-Europe awareness survey Bio-USER survey .pdf

solo gestori archivio

Tipologia: PDF editoriale (versione pubblicata dall'editore)
Licenza: Copyright dell'editore
Dimensione 4.32 MB
Formato Adobe PDF
4.32 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/148977
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 1
social impact